Last reviewed · How we verify

valsartan/atenolol — Competitive Intelligence Brief

valsartan/atenolol (valsartan/atenolol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Beta-blocker combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker / Beta-blocker combination AT1 receptor (angiotensin II type 1) / Beta-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

valsartan/atenolol (valsartan/atenolol) — Novartis. This combination drug lowers blood pressure by blocking angiotensin II receptors (valsartan) and beta-adrenergic receptors (atenolol) to reduce vasoconstriction and heart rate.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
valsartan/atenolol TARGET valsartan/atenolol Novartis marketed Angiotensin II receptor blocker / Beta-blocker combination AT1 receptor (angiotensin II type 1) / Beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Beta-blocker combination class)

  1. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). valsartan/atenolol — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-atenolol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: